Protagonist and takeda announce asco plenary presentation highlighting full 32-week results from phase 3 verify study of rusfertide, showing reductions in phlebotomy, improved hematocrit control in polycythemia vera

Newark, calif. & osaka, japan & cambridge, mass.--(business wire)--protagonist therapeutics, inc. (“protagonist”) (nasdaq:ptgx) and takeda (tse:4502/nyse:tak) announced detailed results from the phase 3, randomized, placebo-controlled verify study evaluating rusfertide in patients with polycythemia vera (pv), which met the primary and all key secondary endpoints. the data will be presented as a late-breaking oral presentation at the 61st american society of clinical oncology (asco) annual meeti.
TAK Ratings Summary
TAK Quant Ranking